Recently, Singclean Medical and the HTL BIOTECHNOLOGY announced a strategic cooperation to inject new vitality and innovation into the medical field. This cooperation aims to give full play to the advantages of both parties in terms of production strength, R&D capabilities and internationalization strategies, jointly create higher-quality medical products, and help patients around the world obtain better medical services.

As a leading supplier of hyaluronic acid raw materials (a leader in pharmaceutical-grade HA and PDRN/DNA expertise and a unique biopolymer product portfolio), HTL BIOTECHNOLOGY has established a strong presence in the international market with its strong production strength and continuous innovation capabilities. Enjoy a great reputation. This cooperation with Singclean Medical will give full play to HTL BIOTECHNOLOGY's professional technology and rich experience in the field of hyaluronic acid, bringing more cooperation opportunities and development space to both parties.

At the same time, as a medical device company that focuses on product quality and customer experience, Singclean Medical is extremely cautious in selecting partners. Cooperation with HTL BIOTECHNOLOGY Company is not only a recognition of the strength and credibility of both parties, but also a guarantee of product quality and a commitment to patient safety.

This cooperation also marks an important step for Singclean Medical in its globalization strategy. Through this cooperation, Singclean Medical will more actively expand overseas markets, accelerate the process of product internationalization, and provide global customers with better and more convenient medical solutions.

The significance of this cooperation is not only to join forces, but also to inject new impetus into the development and international integration of the medical industry. Both parties will work together to actively promote innovation and progress in medical technology and bring more well-being and health to patients around the world.